Acurx Pharmaceuticals LLC
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $43.12 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Acurx Pharmaceuticals LLC had its IPO on 2021-06-25 under the ticker symbol ACXP.
The company operates in the Healthcare sector and Biotechnology industry. Acurx Pharmaceuticals LLC has a staff strength of 4 employees.
Shares of Acurx Pharmaceuticals LLC opened at $3.31 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $3.28 - $3.55, and closed at $3.54.
This is a +6.95% increase from the previous day's closing price.
A total volume of 2,887 shares were traded at the close of the day’s session.
In the last one week, shares of Acurx Pharmaceuticals LLC have increased by +5.36%.
Acurx Pharmaceuticals LLC's Key Ratios
Acurx Pharmaceuticals LLC has a market cap of $43.12 million, indicating a price to book ratio of 4.3934 and a price to sales ratio of 0.
In the last 12-months Acurx Pharmaceuticals LLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Acurx Pharmaceuticals LLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Acurx Pharmaceuticals LLC’s operating margin was 0% while its return on assets stood at -55.23% with a return of equity of -95.34%.
In Q3, Acurx Pharmaceuticals LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Acurx Pharmaceuticals LLC’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acurx Pharmaceuticals LLC’s profitability.
Acurx Pharmaceuticals LLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.5195. Its price to sales ratio in the trailing 12-months stood at 0.
Acurx Pharmaceuticals LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.95 million
- Total Liabilities
- $1.18 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Acurx Pharmaceuticals LLC ended 2023 with $10.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.95 million while shareholder equity stood at $9.76 million.
Acurx Pharmaceuticals LLC ended 2023 with $0 in deferred long-term liabilities, $1.18 million in other current liabilities, 11593.00 in common stock, $-35380574.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.61 million and cash and short-term investments were $10.61 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Acurx Pharmaceuticals LLC’s total current assets stands at $10.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.18 million and inventory worth $0.
In 2023, Acurx Pharmaceuticals LLC's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Acurx Pharmaceuticals LLC paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Acurx Pharmaceuticals LLC stock is currently trading at $3.54 per share. It touched a 52-week high of $4.85 and a 52-week low of $4.85. Analysts tracking the stock have a 12-month average target price of $13.33.
Its 50-day moving average was $3.57 and 200-day moving average was $3.57 The short ratio stood at 1.04 indicating a short percent outstanding of 0%.
Around 2118.1% of the company’s stock are held by insiders while 1176.5% are held by institutions.
Frequently Asked Questions About Acurx Pharmaceuticals LLC
Similar Industry Stocks (Biotechnology)
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.